{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:46:26Z","timestamp":1787064386920,"version":"build-2736575974"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:00:00Z","timestamp":1758499200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004480","name":"Natural Science Foundation of Shanxi Province","doi-asserted-by":"crossref","award":["202203021222356"],"award-info":[{"award-number":["202203021222356"]}],"id":[{"id":"10.13039\/501100004480","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004480","name":"Natural Science Foundation of Shanxi Province","doi-asserted-by":"crossref","award":["202203021222356"],"award-info":[{"award-number":["202203021222356"]}],"id":[{"id":"10.13039\/501100004480","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Kidney360"],"published-print":{"date-parts":[[2026,1]]},"abstract":"\n Key Points<\/jats:title>\n \n \n \n \n In this study, we explored the role and mechanisms underlying the Wnt\/\n \u03b2<\/jats:italic>\n -catenin signaling pathway in the development of renal interstitial fibrosis\n <\/jats:p>\n <\/jats:list-item>\n \n \n Saracatinib effectively inhibits this pathway by binding to Fyn in kidney tissues, blocking the phosphorylation of\n \u03b2<\/jats:italic>\n -catenin at tyrosine 142.\n <\/jats:p>\n <\/jats:list-item>\n \n These findings suggest that saracatinib may offer a promising new therapeutic strategy for CKD treatment.<\/jats:p>\n <\/jats:list-item>\n <\/jats:list>\n <\/jats:p>\n <\/jats:sec>\n \n Background<\/jats:title>\n \n Renal interstitial fibrosis is a common pathologic feature of CKD and is a critical determinant of disease progression. Recent studies have highlighted the significant role of the Wnt\/\n \u03b2<\/jats:italic>\n -catenin signaling pathway in the development of renal interstitial fibrosis, but the exact mechanisms remain unclear.\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n Renal tissue samples from CKD patients with renal interstitial fibrosis who underwent renal biopsy at our center between January 2022 and December 2023 were selected for staining. In addition, a rat model of renal interstitial fibrosis was established using unilateral ureteral obstruction (UUO). UUO rats were administered low and high doses of saracatinib\n via<\/jats:italic>\n gavage for 2 weeks, followed by examination of changes in relevant indicators.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n In this study, we showed that in the kidney tissues of both CKD patients and rats with renal interstitial fibrosis, there was a marked upregulation of the tyrosine 142 kinase Fyn, which accompanied the excessive activation of the Wnt\/\n \u03b2<\/jats:italic>\n -catenin pathway. Saracatinib was found to inhibit this pathway by binding to Fyn in kidney tissues, thereby blocking the phosphorylation of\n \u03b2<\/jats:italic>\n -catenin at tyrosine 142. This inhibition (\n 1<\/jats:italic>\n ) decreased the serum urea nitrogen and cystatin C levels, along with an increase in serum albumin and total protein concentration, and (\n 2<\/jats:italic>\n ) alleviated renal interstitial fibrosis in the UUO rat model, resulting in an amelioration of the progression of renal interstitial fibrosis.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n This study suggests that saracatinib may be a novel therapeutic strategy for CKD treatment.<\/jats:p>\n <\/jats:sec>","DOI":"10.34067\/kid.0000000972","type":"journal-article","created":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T16:03:54Z","timestamp":1758557034000},"page":"25-34","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Saracatinib Delays the Progression of Renal Interstitial Fibrosis by Inhibiting the Wnt\/\u03b2-Catenin Pathway"],"prefix":"10.34067","volume":"7","author":[{"given":"Junjun","family":"Ma","sequence":"first","affiliation":[{"name":"Department of Thoracic Surgery, Fifth Hospital of Shanxi Medical University (Shanxi Provincial People's Hospital), Taiyuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Jiao","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Fifth Hospital of Shanxi Medical University (Shanxi Provincial People's Hospital), Taiyuan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingwei","family":"Liu","sequence":"additional","affiliation":[{"name":"Shanxi Provincial Key Laboratory of Kidney Disease, Fifth Hospital of Shanxi Medical University (Shanxi Provincial People's Hospital), Taiyuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0365-7409","authenticated-orcid":false,"given":"Xiao","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Fifth Hospital of Shanxi Medical University (Shanxi Provincial People's Hospital), Taiyuan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,9,22]]},"reference":[{"issue":"1","key":"B1-20260129","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41581-020-00363-6","article-title":"Sustainable development goals relevant to kidney health: an update on progress","volume":"17","author":"Luyckx","year":"2021","journal-title":"Nat Rev Nephrol."},{"issue":"13","key":"B2-20260129","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1001\/jama.2019.14745","article-title":"Chronic kidney disease diagnosis and management: a review","volume":"322","author":"Chen","year":"2019","journal-title":"Jama-j Am Med Assoc."},{"issue":"10225","key":"B3-20260129","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/S0140-6736(19)32977-0","article-title":"The global burden of chronic kidney disease","volume":"395","author":"Cockwell","year":"2020","journal-title":"Lancet."},{"issue":"10225","key":"B4-20260129","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","article-title":"Global, regional, and National Burden of Chronic Kidney Disease, 1990\u20132017: A Systematic analysis for the global Burden of disease study 2017","volume":"395","year":"2020","journal-title":"Lancet."},{"issue":"1","key":"B5-20260129","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41392-023-01379-7","article-title":"Kidney fibrosis: from mechanisms to therapeutic Medicines","volume":"8","author":"Huang","year":"2023","journal-title":"Signal Transduct Target Ther."},{"issue":"1","key":"B6-20260129","doi-asserted-by":"crossref","first-page":"408","DOI":"10.3390\/ijms22010408","article-title":"Fibrosis in chronic kidney disease: pathogenesis and Consequences","volume":"22","author":"Panizo","year":"2021","journal-title":"Int J Mol Sci."},{"issue":"2","key":"B7-20260129","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00109-019-01870-1","article-title":"Deletion of FHL2 in fibroblasts attenuates fibroblasts activation and kidney fibrosis via restraining TGF-\u03b21-induced Wnt\/\u03b2-catenin signaling","volume":"98","author":"Duan","year":"2020","journal-title":"J Mol Med."},{"issue":"4","key":"B8-20260129","doi-asserted-by":"crossref","first-page":"e35826","DOI":"10.1371\/journal.pone.0035826","article-title":"Receptor tyrosine kinases activate canonical WNT\/\u03b2-catenin signaling via MAP kinase\/LRP6 pathway and direct \u03b2-catenin phosphorylation","volume":"7","author":"Krejci","year":"2012","journal-title":"PLoS One."},{"issue":"5","key":"B9-20260129","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s00018-019-03221-2","article-title":"Src and Fyn define a new signaling cascade activated by canonical and non-canonical Wnt ligands and required for gene transcription and cell invasion","volume":"77","author":"Villarroel","year":"2020","journal-title":"Cell. Mol. Life Sci."},{"issue":"6","key":"B10-20260129","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1111\/j.1523-1755.2004.00641.x","article-title":"Matrilysin (Mmp-7) expression in renal tubular damage: association with Wnt4","volume":"65","author":"Surendran","year":"2004","journal-title":"Kidney Int."},{"issue":"1","key":"B11-20260129","doi-asserted-by":"crossref","first-page":"e23529","DOI":"10.1002\/dvg.23529","article-title":"Epithelial-mesenchymal plasticity in kidney fibrosis","volume":"62","author":"Hadpech","year":"2024","journal-title":"Genesis."},{"issue":"3","key":"B12-20260129","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.3892\/mmr.2017.6884","article-title":"Thromboxane A2 receptor antagonist SQ29548 suppresses the LPS-induced release of inflammatory cytokines in BV2 microglia cells via suppressing MAPK and NF-\u03baB signaling pathways","volume":"16","author":"Yan","year":"2017","journal-title":"Mol Med Rep."},{"issue":"1","key":"B13-20260129","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s10549-023-06873-8","article-title":"Aromatase inhibition plus\/minus Src inhibitor saracatinib (Azd0530) in advanced breast cancer therapy (aristacat): a randomised phase II study","volume":"199","author":"Oswald","year":"2023","journal-title":"Breast Cancer Res Treat."},{"issue":"10","key":"B14-20260129","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1093\/annonc\/mdu363","article-title":"A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer\u2020","volume":"25","author":"McNeish","year":"2014","journal-title":"Ann Oncol."},{"issue":"3","key":"B15-20260129","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1007\/s10637-011-9650-4","article-title":"A phase II trial of the Src kinase inhibitor saracatinib (AZD0530) in patients with metastatic or locally advanced gastric or gastro esophageal junction (GEJ) adenocarcinoma: a trial of the Pmh phase II consortium","volume":"30","author":"Mackay","year":"2012","journal-title":"Invest New Drugs."},{"key":"B16-20260129","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3389\/fnins.2020.00045","article-title":"Src inhibition attenuates neuroinflammation and protects dopaminergic neurons in Parkinson's disease models","volume":"14","author":"Yang","year":"2020","journal-title":"Front Neurosci."},{"key":"B17-20260129","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/1742-2094-9-117","article-title":"Inhibition of Src kinase activity attenuates amyloid associated microgliosis in a murine model of Alzheimer's disease","volume":"9","author":"Dhawan","year":"2012","journal-title":"J Neuroinflammation."},{"issue":"12","key":"B18-20260129","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1164\/rccm.202010-3832OC","article-title":"Saracatinib, a selective Src kinase inhibitor, blocks fibrotic responses in preclinical models of pulmonary fibrosis","volume":"206","author":"Ahangari","year":"2022","journal-title":"Am J Respir Crit Care Med."},{"issue":"1","key":"B19-20260129","doi-asserted-by":"crossref","first-page":"5637","DOI":"10.1038\/s41467-022-33193-0","article-title":"Airway basal cells show a dedifferentiated Krt17(High)Phenotype and promote fibrosis in idiopathic pulmonary fibrosis","volume":"13","author":"Jaeger","year":"2022","journal-title":"Nat Commun."},{"issue":"2","key":"B20-20260129","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41419-020-2229-2","article-title":"Targeting Src family kinase member Fyn by saracatinib attenuated liver fibrosis in vitro and in vivo","volume":"11","author":"Du","year":"2020","journal-title":"Cell Death Dis."},{"issue":"3","key":"B21-20260129","doi-asserted-by":"crossref","first-page":"e17929","DOI":"10.1371\/journal.pone.0017929","article-title":"Activation of Src mediates pdgf-induced Smad1 phosphorylation and Contributes to the progression of glomerulosclerosis in Glomerulonephritis","volume":"6","author":"Mima","year":"2011","journal-title":"PLoS One."},{"issue":"5","key":"B22-20260129","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/s41581-020-0268-7","article-title":"The impact of chronic kidney disease on global health","volume":"16","author":"Carney","year":"2020","journal-title":"Nat Rev Nephrol."},{"key":"B23-20260129","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.mam.2018.06.002","article-title":"Cellular and molecular mechanisms of kidney fibrosis","volume":"65","author":"Djudjaj","year":"2019","journal-title":"Mol Aspects Med."},{"issue":"1","key":"B24-20260129","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/ptr.7599","article-title":"Quercetin inhibits the amphiregulin\/Egfr signaling-mediated renal tubular epithelial-mesenchymal transition and renal fibrosis in obstructive nephropathy","volume":"37","author":"Wang","year":"2023","journal-title":"Phytother Res."},{"issue":"2","key":"B25-20260129","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/sj.ki.5000054","article-title":"Renal fibrosis: new insights into the pathogenesis and therapeutics","volume":"69","author":"Liu","year":"2006","journal-title":"Kidney Int."},{"issue":"1","key":"B26-20260129","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00109-017-1606-5","article-title":"\u03b2-Arrestin-1 deficiency ameliorates renal interstitial fibrosis by blocking Wnt1\/\u03b2-catenin signaling in mice","volume":"96","author":"Xu","year":"2018","journal-title":"J Mol Med."},{"key":"B27-20260129","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/bs.ctdb.2016.09.003","article-title":"Ror-family receptor tyrosine kinases","volume":"123","author":"Stricker","year":"2017","journal-title":"Curr Top Dev Biol."},{"issue":"5","key":"B28-20260129","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1002\/hep.28790","article-title":"An infernal cross-talk between oncogenic \u03b2-catenin and c-Met in hepatocellular carcinoma: evidence from mouse modeling","volume":"64","author":"Pascale","year":"2016","journal-title":"Hepatology."},{"issue":"5","key":"B29-20260129","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1002\/hep.29661","article-title":"\u03b2-catenin deficiency in hepatocytes aggravates hepatocarcinogenesis driven by oncogenic \u03b2-catenin and MET","volume":"67","author":"Liang","year":"2018","journal-title":"Hepatology."},{"issue":"7","key":"B30-20260129","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1128\/MCB.23.7.2287-2297.2003","article-title":"P120 catenin-associated fer and Fyn tyrosine kinases regulate beta-catenin tyr-142 phosphorylation and beta-catenin-alpha-catenin interaction","volume":"23","author":"Piedra","year":"2003","journal-title":"Mol Cell Biol."},{"key":"B31-20260129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2023\/9296092","article-title":"The molecular basis of wnt\/\u03b2-catenin signaling pathways in neurodegenerative diseases","volume":"2023","author":"Anand","year":"2023","journal-title":"Int J Cell Biol."},{"key":"B32-20260129","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ceb.2014.08.003","article-title":"Casein kinase 1 and Wnt\/\u03b2-catenin signaling","volume":"31","author":"Cruciat","year":"2014","journal-title":"Curr Opin Cell Biol."},{"issue":"1-2","key":"B33-20260129","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s11010-011-0965-4","article-title":"CK2 functionally interacts with AKT\/PKB to promote the \u03b2-catenin-dependent expression of survivin and enhance cell survival","volume":"356","author":"Ponce","year":"2011","journal-title":"Mol Cell. Biochem."},{"key":"B34-20260129","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.trsl.2023.11.006","article-title":"Metadherin orchestrates PKA and PKM2 to activate \u03b2-catenin signaling in podocytes during proteinuric chronic kidney disease","volume":"266","author":"Chen","year":"2024","journal-title":"Transl Res."}],"container-title":["Kidney360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0000000972","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T20:03:29Z","timestamp":1786478609000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0000000972"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,22]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.34067\/kid.0000000972","relation":{},"ISSN":["2641-7650"],"issn-type":[{"value":"2641-7650","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,22]]},"assertion":[{"value":"2025-04-10","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-08","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}